Valion Bio Stock Price, News & Analysis
Company Description
Valion Bio, Inc. develops immunotherapeutic biologics based on Toll-like receptor 5, or TLR5, activation for cytoprotection and immune modulation. The company, formerly known as Tivic Health Systems, Inc., trades on Nasdaq under the symbol VBIO and operates as a clinical-stage biopharmaceutical company. Its lead program is Entolimod™, a TLR5 agonist being developed for Acute Radiation Syndrome, oncology supportive care, and longevity-related indications.
Entolimod is designed to activate innate immune pathways, including cytoprotective signaling relevant to bone marrow and gastrointestinal tissue preservation after ionizing radiation exposure. The Acute Radiation Syndrome program is positioned as a medical countermeasure for radiological threats, and the company has described FDA Fast Track and Orphan Drug designations for Entolimod in ARS. Valion Bio also links Entolimod's mechanism to oncology supportive care, including potential treatment of neutropenia, a condition commonly associated with chemotherapy, and lymphocyte exhaustion, a state of T-cell dysfunction.
The company's pipeline also includes Entolasta™, a next-generation TLR5 agonist intended to broaden the therapeutic reach of the same innate-immunity platform. Entolasta provides additional pipeline depth in areas that include oncology supportive care and other applications where TLR5-mediated immune modulation may be relevant.
Pipeline and manufacturing model
Valion Bio combines drug development with internal biomanufacturing capabilities through Velocity Bioworks, its wholly owned contract development and manufacturing organization. Velocity Bioworks provides biomanufacturing services to third-party biotechnology companies and also supports Valion Bio's own biologics pipeline. This structure gives the company an operating model that includes clinical-stage therapeutic development and CDMO service activity within the same corporate group.
The company is headquartered in San Antonio, Texas. Its current corporate identity reflects a completed rebranding from Tivic Health Systems to Valion Bio, with the ticker change to VBIO effective in April 2026. The name change marks the company's stated transition from its prior health-technology identity to a biopharmaceutical platform centered on Entolimod, Entolasta, innate immunity, and biologics manufacturing.
Stock Performance
Valion Bio (VBIO) stock last traded at $0.8800, down 4.39% from the previous close. Over the past 12 months, the stock has lost 12.9%. At a market capitalization of $2.9M, VBIO is classified as a micro-cap stock with approximately 3.1M shares outstanding.
VBIO Rankings
Latest News
Valion Bio has 10 recent news articles, with the latest published 3 days ago. Of the recent coverage, 2 articles coincided with positive price movement and 4 with negative movement. Key topics include earnings, earnings date, clinical trial. View all VBIO news →
SEC Filings
Valion Bio has filed 10 recent SEC filings, including 4 Form 10-Q, 4 Form 8-K, 2 Form SCHEDULE 13G/A. The most recent filing was submitted on May 14, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all VBIO SEC filings →
Financial Highlights
operating income reached -$7.9M, and net income was -$8.9M. The company generated -$7.0M in operating cash flow. With a current ratio of 20.13, the balance sheet reflects a strong liquidity position.
Upcoming Events
First BioScan-NMR installation
Valion Bio has 1 upcoming scheduled event. The next event, "First BioScan-NMR installation", is scheduled for July 1, 2026 (in 44 days). Investors can track these dates to stay informed about potential catalysts that may affect the VBIO stock price.
Short Interest History
Days to Cover History
VBIO Company Profile & Sector Positioning
Valion Bio (VBIO) operates in the Biotechnology industry within the broader Electromedical & Electrotherapeutic Apparatus sector and is listed on the NASDAQ.